Argos Therapeutics, Inc. ("Argos") is a biopharmaceutical company focused on the development and commercialization of personalized immunotherapies for the treatment of cancer and infectious disease.

According to the law firm press release, Argos’ product candidate AGS-003 (rocapuldencel-T) is being evaluated in a pivotal ADAPT Phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). The complaint alleges that Argos issued materially false and/or misleading statements, causing the stock to trade at artificially inflated prices; following the release of adverse information, shares of Argos plummeted, damaging investors. In particular, the complaint alleges that Argos issued materially false and/or misleading information regarding the success and potential of its drug candidate AGS-003 (rocapuldencel-T).

On February 22, 2017, despite positive statements made by the Company, Argos then announced that the ADAPT study would be discontinued for futility. Following this news, shares of Argos fell approximately 66% to close at $1.48 per share on February 22, 2017.

On June 23, 2017, the Court appointed Co-Lead Plaintiffs and Lead Counsel.

On September 19, 2017, the parties filed a Stipulation expressing their intent to voluntarily dismiss this action. Pursuant to the Stipulation, the Court ordered this case dismissed on September 26.